Zavesca ^*

Zavesca should not be doubled up if you miss a dose. If you forget to take your scheduled dose, simply skip it and take your next dose at the regular time. Taking two doses too close together can increase your risk of experiencing side effects like diarrhea or tremors. Maintaining a consistent schedule is important for the medication to work effectively.

Zavesca may cause side effects like dizziness, which can be worsened by alcohol. It is generally recommended to limit or avoid alcohol consumption while you are on this treatment. Alcohol does not directly interfere with the medication's mechanism, but combining them could impair your coordination and judgment. Always consult your doctor for personalized advice regarding alcohol use.

Zavesca begins working after you start taking it, but noticeable improvements may take several months. For Gaucher disease, it can take six months to a year to see significant changes in liver size or blood counts. For Niemann-Pick type C disease, the primary goal is to stabilize and slow the progression of neurological symptoms, which is a gradual process monitored by your doctor.

Zavesca commonly causes weight loss, especially during the initial phase of treatment. This happens because of side effects like diarrhea and decreased appetite. Your doctor will monitor your weight regularly. It is important to maintain a balanced diet and communicate with your healthcare provider if you experience significant or unintended weight loss. They may adjust your diet or treatment plan.

Zavesca often causes diarrhea, which can usually be managed. Your doctor may recommend dietary changes, such as avoiding high-carbohydrate foods, lactose, and sugary drinks. Eating smaller, more frequent meals can also help. If the diarrhea is severe or persistent, your doctor might suggest a temporary dose reduction or prescribe anti-diarrheal medication like loperamide. Stay hydrated by drinking plenty of fluids.

Zavesca can cause fine tremors, particularly in the hands. This is a known neurological side effect. You should inform your doctor if you develop any new or worsening tremors, shakiness, or unsteadiness. They will perform a neurological examination to assess the situation. In some cases, the dose may need to be adjusted or treatment might be discontinued if the symptom is severe.

Zavesca is not a chemotherapy drug. It is classified as a substrate reduction therapy. Instead of killing cells, it works by inhibiting an enzyme to reduce the production of harmful fatty substances that build up in the body due to Gaucher and Niemann-Pick type C diseases. This targeted action helps manage the underlying metabolic problem without the widespread effects of chemotherapy.

Zavesca should be used with caution if you have kidney problems. Since the medication is cleared from the body by the kidneys, impaired kidney function can cause the drug to build up, increasing the risk of side effects. Your doctor will assess your kidney function before starting treatment and may prescribe a lower starting dose if you have mild or moderate renal impairment. It is contraindicated in severe kidney disease.

Zavesca should be stored at room temperature, below 86°F (30°C), in its original container. Keep the capsules in a dry place away from moisture, heat, and direct sunlight. It is also crucial to store the medication in a location that is safely out of the reach of children and pets to prevent accidental ingestion. Do not use any capsules that have passed their expiration date.

Zavesca is not recommended for women who are pregnant or trying to become pregnant, as it may harm the developing fetus. Women of childbearing potential must use reliable contraception before starting Zavesca, during treatment, and for a period after stopping. Men on Zavesca should also use contraception, as the medication can be present in semen. Consult your doctor about family planning.

Zavesca is specifically approved for the treatment of type 1 Gaucher disease in adults. It is not indicated for type 2 or type 3 Gaucher disease, which involve more severe neurological symptoms. Type 1 is the most common form and primarily affects the internal organs and bones without the severe, early-onset brain damage seen in the other types. Your doctor will diagnose your specific type.

Zavesca differs from ERT in its administration and mechanism. ERT is given via intravenous (IV) infusions, replacing the missing enzyme. In contrast, Zavesca is an oral pill that works by reducing the body’s production of the fatty substance that the missing enzyme would normally break down. Zavesca is often used when a patient is not a suitable candidate for ERT infusions.